Cell and gene therapy companies can shape the UK’s industrial strategy
Advanced therapy medicinal products (ATMPs), such as new cell and gene therapies (CGTs), offer potentially life-changing health benefits to patients with different types of cancers and rare diseases, but there is growing evidence of the challenges businesses face in developing such treatments and making them accessible to patients.
